FDA grants accelerated approval to BCL-2 inhibitor sonrotoclax for mantle cell lymphoma. Lawrence L. Cancer 2026;132:e70537.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lawrence L. FDA grants accelerated approval to BCL-2 inhibitor sonrotoclax for mantle cell lymphoma. Cancer 2026;132:e70537.
PMID: 42676089